Pharmaceuticals and Healthcare Report has been researched at
source and features the latest available data and forecasts to
end-2013 covering drugs and healthcare expenditure, the
prescription, OTC and generics markets, and foreign trade; company
rankings and competitive landscapes including multinational and
national drugs companies; and analysis of latest industry news,
trends and regulatory developments.
Business Monitor International’s
Pharmaceuticals and Healthcare Report provides industry
professionals, market investors and corporate and financial
services analysts with independent forecasts and competitive
intelligence on theThai
pharmaceutical and healthcare industry.
Key Benefits of Report
- Benchmark BMI’s Independent 5-year
Pharmaceutical and Healthcare Industry Forecasts on
to test other views – a key input
for successful budgeting and strategic business planning in the
pharmaceutical and healthcare market.
- Target Business Opportunities & Risks
Pharmaceutical and Healthcare Sector
through our reviews of latest industry trends, regulatory
changes and major deals, projects and investments in
- Exploit The Latest Competitive
Pharmaceutical and Healthcare Intelligence & company SWOTS
on your competitors and peers through company rankings by sales,
market share and ownership structure – includes multi-national
and national companies inThailand.
Executive Summary & Industry SWOT
An at-a-glance perspective on latest regulatory
developments, key forecast indicators and major corporate
developments, covering the prescription, OTC and generics markets.
The SWOT outlines strategic factors which affect BMI’s forecast
analysis, and taken together with BMI’s Economic and Business
Environment SWOTS, give a complete overview of market climate.
Outline of market characteristics, growth
factors, leading therapeutic segments and a competitivness of the
Guide to and analysis of country intellectual
property developments and pricing & reimbursement issues, which
constitute the regulatory make-up of the market.
Focus on government healthcare reforms,
epidemiological trends, company M&As, product launches, market
entries, FDI activity, R&D and patent legislation.